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with and without abscopal responses was respectively of 22.4 
months (range 2,5-50,3) and 8,3 months (range 7,6-9.0). 11 
out of 13 patients with local response showed an abscopal 
effect. 
 
Conclusion: The RT after ipilimumab treatment may be an 
option for further potentiate its effect. Local response to RT 
might be predictive for the abscopal response and outcome. 
Further studies are warranted in this field to better 
understand and define the role of RT in combination or 
sequencing with ipilimumab treatment. 
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Purpose or Objective: The aim of this study was to analyze 
differences in radiological responses of melanoma brain 
metastases after Gamma Knife radiosurgery and their 
correlation with patient survival. 
 
Material and Methods: We retrospectively analyzed 78 
patients treated with Gamma Knife radiosurgery for 
melanoma brain metastases between 2009 and 2015 in the 
Radiosurgical centre (Saint-Petersburg, Russia) and subjected 
to follow-up MRI examinations. Patients receiving BRAF 
inhibitor therapy or ipilimumab were not included in the 
study. The study group consisted of 39 men and 39 women 
with a mean age of 52 years. The median KPS was 80 %. 
According to RPA, 14 patients were in Class I, 61 patients in 
Class II, and 3 patients in Class III. Most of the patients 
presented with multiple brain metastases (87 %). 
Radiosurgery was performed with Gamma Knife 4C and 
Perfection units; the mean dose delivered to the tumor 
margin was 20 Gy at 50 % isodose. After treatment, the 
patients underwent control MRI examination with standard 
protocols (2 mm T2 and 1 mm T1 with double contrast 
enhancement) at 8 weeks and at regular 3-month intervals 
thereafter. MR images were analyzed with Gamma Plan 
software. Volumetric measurements of metastases on pre- 
and post-treatment images were performed in order to 
determine different types of radiological response. We 
divided the patients into groups according to the type of 
radiological response and compared Kaplan-Meier survival 
curves in these groups with the long-rank test. 
 
Results: We found that patients with melanoma brain 
metastases had different radiological reactions to Gamma 
Knife radiosurgery. We distinguished several types of 
radiation response: sustained decrease in tumor volume, 
prolonged stabilization of tumor volume, transient increase in 
tumor volume due to intratumoral bleeding with subsequent 
decrease in tumor size, transient increase in tumor volume 
due to radiation-induced necrosis followed by tumor 
shrinkage. Statistical analysis revealed that a rapid decrease 
in tumor volume was associated with poor prognosis. Median 
overall survival of this group of patients was about two times 
less compared with patients whose radiation response 
developed slowly after the first 2 months of radiosurgery (p < 
0.0001). Stratification to RPA classes revealed that patients 
with a rapid response have poorer survival prognosis than 
those with a slow response in the corresponding RPA classes. 
 
Conclusion: Melanoma brain metastases showed different 
radiological responses to radiosurgery. Rapid shrinkage of 
brain metastases is associated with poor survival, which may 
indicate more aggressive biological behavior of this tumor 
subtype. Different radiation sensitivity of melanoma brain 
metastases to Gamma Knife radiosurgery may be associated 
with molecular characteristics of cell subpopulations, which 
determine biological tumor behavior and affect patient 
prognosis. 
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Purpose or Objective: Adult T-cell leukemia–lymphoma 
(ATLL) is a rare disease and a peripheral T-cell malignancy 
associated with human T-cell lymphotropic virus type I 
(HTLV-1) infection. ATLL treatment is based on 
subclassification, and intensive multidrug chemotherapy 
regimens are often used for aggressive subtypes. However, 
disease progression occurs in most of patients. There are only 
a few reports for the radiotherapy in patients with ATLL. 
Therefore, the role of radiotherapy for ATLL is not well 
investigated even for the palliation. The purpose of this study 
was to evaluate the efficacy and toxicity for the radiotherapy 
in patients with ATLL. 
 
Material and Methods: Between April 1983 to October 2013, 
44 patients with 205 ATLL tumor lesions were treated with 
radiotherapy at our institution. Sites of tumor lesions were as 
follows; 184 lesions were in the skin, 13 lesions in the lymph 
nodes, 6 lesions in the central nerves system, and 2 lesions in 
the bone. Acute type on ATLL subtypes was seen in 8 
patients, chronic type in 7 patients, lymphoma type in 10 
patients, smoldering type in 15 patients and others in 4 
patients. Median total dose of radiotherapy was 29Gy (range, 
2-60Gy), and the median fractionated dose was 3Gy (range, 
1-7Gy). For the skin tumor lesions, 45Gy in 15 fractions was 
selected in 33 lesions, 30Gy in10 fractions in 38 lesions, 28Gy 
in 4 fractions in 21 lesions and 20Gy in 5 fractions in 19 
lesions and others in 73 lesions. Only 4 of 44 patients were 
treated with total skin irradiation, and the remaining 40 
patients received conventional radiotherapy for local tumor. 
Efficacy and toxicity of the radiotherapy for ATLL were 
retrospectively evaluated, and the predictors of a long-term 
survival were analyzed. 
 
Results: The median follow-up period was 206 days. 
Objective tumor response rates were 98%. Four of 6 tumor 
lesions with stable disease or progressive disease on 
objective tumor response were associated with aggressive 
subtypes or tumor sites of the central nerves system. In-field 
recurrence after radiotherapy was recognized in 3 (2%) 
lesions. Two-year and 5-year overall survival rates were 76% 
and 44%, respectively. Median overall survival time in 
patients with indolent subtypes (chronic or smoldering type) 
of ATLL was 23 months, while that in patients with aggressive 
subtypes (acute or lymphoma type) was 6 months, and the 
difference was significant. Acute toxicities of Grade 2 
dermatitis were seen in 3 patients. Acute toxicity of Grades 
3–5 was not observed. Late toxicity of ≥Grade 2 was also not 
recognized. 
 
Conclusion: Radiotherapy for ATLL was mainly used for the 
skin lesion and well tolerated, and could achieve excellent 
local tumor control without inducing severe toxicity. 
Radiotherapy should be selected to improve the quality of 
life, and be incorporated into combined modality therapy for 
ATLL. 
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Purpose or Objective: To evaluate local control, 
enucleation-free survival, toxicity and cost-effectiveness in 
patients with choroidal melanoma treated with linac-based 
stereotactic radiosurgery (SRS). GammaKnife® radiosurgery 
has report very good results for this melanoma treatment.  
 
Material and Methods: Between 2003-2014, 6 patients with 
choroidal melanoma were treated at NISA Virgen del 
Consuelo Hospital in Valencia, Spain. Mean age was 59 years 
(range 43-79). Three were men and three women. Metastatic 
disease was ruled out in all cases. Two patients had small 
tumors, two medium sized lesions and two had large lesions 
according to Collaborative Ocular Melanoma Study 
Classification. Mean tumor volume was 0,49 cm3 (range 0,17-
0,93). Three tumors were localized in the right eye. Visual 
field previous to treatment was normal in 5 cases and one 
patient presented complete hemianopsia of the affected eye. 
Central vision was preserved in all cases. The procedure was 
made under sedation and retrobulbar blockage, the eye 
muscles were fixed to Leksell G-Frame with silk sutures. 
Magnetic resonance (MRI) and computed tomography (CT) 
were used to contour lesion. CTV minimal marginal dose is 30 
Gy, encompassed the 80 % isodose line in 4 patients and the 
60% and 55% isodose lines in the other cases. All were treated 
with 6 MV linac, one isocenter and cone-colimation. Global 
cost of this method is around 8.000 € (range 7.000-12.000). It 
is an ambulatory procedure with a total duration of 3 hours 
or less. 
 
Results: Median follow-up is 19 months (range 1-69). Follow 
up includes MRI and ophthalmoscopy every 6 months. 
Complete response in one patient, maximal partial response 
(≥ 50%) in three patients, partial response (≤ 50%) in other 
patient and it’s too early for response evaluation (less than 6 
weeks) in the last one. For lens and optic nerve, the dose 
constraints were 4 and 18 Gy, respectively. Up to date, no 
patient has local or distance progression. Enucleation has not 
been necessary in any patients. Five years after treatment 
one patient presented retinal scarring in irradiated area. 
Glaucoma start 9 month after SRS in one patient with 
previous cataract surgery. No other toxicities were observed.  
 
Conclusion: In our experience, linac SRS is effective eye and 
vision-sparing method to treat patients with a minimally 
invasive, safe and cost-efficient alternative to brachytherapy 
and enucleation in choroidal melanoma with high local 
control rates and low incidence of toxicities.  
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Purpose or Objective: The immunotherapy improves survival 
in patients (pts) with metastatic melanoma, but there is 
insufficient data on the efficacy in pts with brain metastases. 
SRS and SRT allow greater local control in pts with melanoma 
brain metastases, with not significant impact on prognosis. 
Our analysis evaluated survival and local control in pts 
treated with SRT/SRS with Cyberknife® system and 
Immunotherapy.  
 
Material and Methods: From November 2012 to September 
2015 we treated 47 pts (26 M and 21 F) with melanoma brain 
metastases. The median age was 59 years (28-81y). 28 pts 
received immunotherapy pre (pre-RT), concomitant and post 
radiation treatment (post-RT). 26 pts received Ipilimumab: 
14 pts pre-RT, 5 pts concomitant-RT, 7 pts post-RT; 2 pts 
received Nivolumab: 1 pt pre-RT and 1 pt concomitant-RT; 11 
pts received Pembrolizumab: 3 pts pre-RT, 4 pts concomitant 
RT, 4 pts post-RT. we treated 91 lesions of average size 13.5 
mm (2-36). Based on the number of lesions, size and 
location, 69 lesions were treated with SRS (10-24Gy), 22 with 
SRT (18-24Gy/2-3-5 fractions). We evaluated the local 
response according to RECIST criteria (complete response CR: 
disappearance of the lesion; partial response PR: at least a 
30% decrease in the diameter of lesion; progression disease 
PD: increase in the diameter of the lesion > 20%; stable 
disease SD: everyone else). We assessed overall survival, 
local control (LC) as the sum of CR, PR and SD, and the 
impact on LC of the association Radiotherapy (RT) and 
immunotherapy. 
 
Results: 41 pts were evaluable for follow-up (FU). The 6-
month survival was 58%. 11 patients died and 11 pts received 
Whole Brain RT for progression disease. At two months FU, of 
the 39 pts evaluable (24 treated with RT and 
immunotherapy), 85% had LC; at four months FU, of 29 pts 
evaluable (20 treated with RT and immunotherapy), 81% had 
LC; at six months FU, the 24 pts evaluable (15 treated with 
RT and Immunotherapy) 100% had LC. 
 
Conclusion: Our analysis seems to confirm the literature data 
in terms of overall survival. The results showed a good 
disease local control in pts treated with SRT/SRS and 
immunotherapy, demonstrating a potential role of 
immunotherapy in the treatment of melanoma brain 
metastases. the recruitment of a greater number of pts, a 
longer follow-up and new prospective studies of combination 
RT and immunotherapy are needed to demonstrate the 
immunotherapy role in the treatment of melanoma brain 
metastases. 
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Purpose or Objective: Adjuvant radiotherapy is proven to 
prevent lymph-node field relapse after therapeutic 
lymphadenectomy for melanoma, but does not improve 
overall survival. Risk factors for lymph-node field recurrence 
include presence of extracapsular extension, number and size 
of lymph nodes at dissection. This study reports patterns of 
failure in patients treated with adjuvant radiotherapy post 
lymphadenectomy for melanoma. 
 
Material and Methods: This retrospective study included all 
patients in three institutions treated with adjuvant 
radiotherapy post lymphadenectomy for melanoma between 
June 2012 and March 2015. 
Patients who received radiotherapy were those with high risk 
of lymph node field recurrence, as per the findings of 
Burmeister et al in 2012. Patients received radiotherapy to 
the head & neck (55%), groin (30%) and axilla (15%). All were 
staged with PET or CT. Both IMRT (50%) and 3D conformal 
(50%) techniques were used. 
 
Results: 20 patients were treated during this period (see 
table). Median follow up was 16 months (range 6.7 - 32 
months).  
There were no lymph node field recurrences. 
Local recurrence rate was 10%. 
Distant recurrence rate was 35%, all occurring within 4 
months from completion of radiotherapy.  
Distant recurrence rate was 53.8% in patients with 
extracapsular extension. 
All patients with local or distant relapse had extracapsular 
extension. 
71% of patients with distant recurrence had PET staging. 
8% of patients experienced grade 3 radiotherapy toxicity. 
 
 
